Publications by authors named "N Gianotti"
Article Synopsis
- Virological failure (VF) of first-line second-generation INSTI-based HIV treatments is uncommon, typically presenting with low viral loads and no drug resistance mutations.
- A retrospective study examined the effectiveness of rescue treatments for patients who experienced VF while on SG-INSTI therapy between 2016 and 2021, focusing on their viral load outcomes.
- Results showed that 75.6% of patients achieved virological success during follow-up, regardless of whether they switched medications or remained on their failing regimen, suggesting spontaneous suppression in many cases.
Article Synopsis
- The study analyzed the CD4+/CD8+ ratio in people with HIV who switched from a standard treatment to a long-acting combination of cabotegravir and rilpivirine.
- Over the course of one year, participants showed a notable improvement in their CD4+/CD8+ ratio, indicating better immune health.
- The results suggest that using long-acting therapy could help improve immune recovery in those already experienced with HIV treatment.
Background: The aim of the study was to evaluate the 12-month cumulative probability of treatment discontinuation (TD) in people with human immunodeficiency virus (HIV; PWH) and a long exposure to antiretroviral therapy (ART) switching to long-acting cabotegravir and rilpivirine (CAB/RPV).
Methods: SCohoLART is a single-center, prospective, cohort study designed to collect both samples and clinical data from PWH with virological suppression who switched to bimonthly long-acting CAB/RPV. TD occurred at switch to another regimen for any reason including virological failure (VF); VF was defined as HIV RNA levels ≥50 copies/mL at 2 consecutive measurements or a single HIV RNA level ≥1000 copies/mL.
Objective: To evaluate the virological outcome of darunavir-cobicistat (DRVc)-based regimens in adults living with HIV who had experienced virological failure (VF) on any previous drug combination.
Methods: This was a retrospective cohort study (CSLHIV Cohort) of adults living with HIV who started a DRVc-based regimen with HIV-RNA >50 copies/mL after VF on any previous drug combination. Data on demographics, antiretroviral treatment since HIV diagnosis, and immunological and metabolic parameters from baseline (start of DRVc) to 48 weeks were analyzed in order to assess the cumulative proportion of those who achieved virological success (VS), defined as at least one instance of HIV-RNA <50 copies/mL within 12 months from baseline.
Objective: Analysis of bictegravir/emtricitabine/tenofovir alafenamide (BFTAF) efficacy and safety in virologically suppressed people living with HIV (PLWH) in clinical practice.
Patients And Methods: The retrospective cohort study, which included adult treatment-experienced and virologically suppressed PLWH, switched to BFTAF from June 2019 to June 2021. Efficacy and safety were evaluated as virological failure (VF=2 consecutive HIV-RNA>50 copies/mL or a single HIV-RNA>400 copies/mL) and treatment failure (TF=VF or discontinuation for any reason) until data freezing (August 2022).